Folylpoly-Glutamate Synthetase Expression Is Associated with Tumor Response and Outcome from Pemetrexed-Based Chemotherapy in Malignant Pleural Mesothelioma

• Published in: Journal of thoracic oncology Vol. 7; no. 9; pp. 1440 - 1448
• Main Authors: Christoph, Daniel C., Asuncion, Bernadette Reyna, Mascaux, Celine, Tran, Cindy, Lu, Xian, Wynes, Murry W., Gauler, Thomas C., Wohlschlaeger, Jeremias, Theegarten, Dirk, Neumann, Volker, Hepp, Rodrigo, Welter, Stefan, Stamatis, Georgios, Tannapfel, Andrea, Schuler, Martin, Eberhardt, Wilfried E., Hirsch, Fred R.
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.09.2012; International Association for the Study of Lung Cancer
• Subjects: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Biomarker; Carboplatin - administration & dosage; Cisplatin - administration & dosage; Female; Follow-Up Studies; Folylpoly-γ-glutamate synthetase; Glutamates - administration & dosage; Guanine - administration & dosage; Guanine - analogs & derivatives; Humans; Male; Malignant pleural mesothelioma; Mesothelioma - drug therapy; Mesothelioma - enzymology; Mesothelioma - pathology; Middle Aged; Neoplasm Staging; Pemetrexed; Peptide Synthases - metabolism; Pleural Neoplasms - drug therapy; Pleural Neoplasms - enzymology; Pleural Neoplasms - pathology; Prognosis; Retrospective Studies; Survival Rate; Thymidylate synthase; Thymidylate Synthase - metabolism; Biomarker; Folylpoly-γ-glutamate synthetase; Malignant pleural mesothelioma; Thymidylate synthase; Pemetrexed

Pemetrexed-based chemotherapy represents the standard of care in first-line treatment of advanced malignant pleural mesothelioma (MPM). However, there are no established predictors of clinical benefit. Pemetrexed inhibits multiple enzymes involved in pyrimidine and purine synthesis, but the main tar...